Riphah Rehabilitation Center
Islamabad, 44000, Pakistan
NCT Number: NCT04924777
The study design is to determine the effectiveness of moderate physical activity on g;lycemic control in type 2 diabetes mellitus.
Looking for future studies?
Notify Me30 year–70 year
All sexes
Interventional
Not applicable
Islamabad, 44000, Pakistan
To the best of authors knowledge so far the studies have been conducted on different modes of moderate physical activity on glycemic control in type 2 diabetes, current study goal is to evaluate which mode of moderate physical activity has more significant result on glycemic control in type 2 diabetes and is sustainable in Pakistani society according to the socioeconomic status and cost effectiveness of the modes of moderate physical activity.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1-Brisk walk for 30 minutes 2-5 days a week 3-3months
1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months
1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months
Time frame: 3 months
Reduction in HbA1c levels
Riphah International University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05411458
Anxiety Disorders, COVID-19
Izmir, Turkey (Türkiye)
View Trial DetailsNCT00467285
Bone Diseases, Bone Diseases, Metabolic
View Trial DetailsNCT02538848
Diabetes Mellitus, Diabetes Mellitus, Type 2
Perth, Australia
View Trial DetailsNCT06353347
Diabetes Mellitus, Diabetes Mellitus, Type 2
Baotou, China
View Trial Details